Strategy for design of antistaphylococcal drugs for immunoprophylaxis and immunotherapy

Gruber I.M., Egorova N.B., Kurbatova E.A., Mikhailova N.A.

I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences, Moscow
Numerous efforts by a number of research organizations to design staphylococcus vaccines have been unsuccessful to this day and there are virtually unavailable effective commercial immunopreparations to control staphylococcal infections. The review presents the results of trials of vaccines designed using the major virulence factors of Staphylococcus aureus. Foremost, these are capsular polysaccharides, alpha-toxin, leukocidin, and surface protein antigens. During the clinical trials, the vaccines based on these antigens proved to be insufficiently effective; in this connection, a start was made to develop polyvalent vaccines by choosing protective antigens. These vaccines were designed on the basis of surface proteins, including iron-regulated ones. There are also attempts to develop vaccines based on polysaccharide-protein compositions obtained from specially selected S.aureus strains. Virtually all multivalent vaccines are passing a clinical stage or phase 1 clinical trial now. To select S. aureus strains and to choose protective antigens are an important condition for preparing an effective staphylococcal vaccine; these have been used to design the vaccine developed at the I.I. Mechnikov Research Institute for Vaccines and Sera, Russian Academy of Medical Sciences.


  1. Natsionalnaya kontseptsiya profilaktiki infektsiy, svyazannyih s okazaniem meditsinskoy pomoschi. Utverzhdena rukovoditelem Federalnoy sluzhbyi po nadzoru v sfere zaschityi prav potrebiteley i blagopoluchiya cheloveka, Glavnyim gosudarstvennyim sanitarnyim vrachom RF G.G. Onischenko 06.11.2011. [National conception of infection prophylaxis, connected with medical rescue. Сonfirmed by Federal Service of Control in the Sphere of Protection the Rights of Consumers and Human Welfare, the Head State Sanitary Inspector of Russia Federation G.G. Onischenko 06.11.2011] (In Russ.)

  2. Kuzmenko O.M., Gruber I.M., Priyatkin R.G. [Prevention and immunotherapy of staphylococcal infections with bacterial vaccines]. Zhurnal Еpidemiologii, Mikrobiologii i Immunologii 2010; 5: 106–112 (In Russ.)

  3. Johri A.K., Paoletti L.C., Glaser P, Dua M., Sharma P.K., Grandi G. et al. Group B Streptococcus: global incidence and vaccine development. Nat. Rev. Microbiol. 2006; 12: 932–942.

  4. O’Riordan K., Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 2004 17(1): 218–34.

  5. Fattom A.I., Sarwar J., Ortiz A., Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 1996; 64(5): 1659–1665.

  6. Lee J.C., Park J.S., Shepherd S.E., Carey V., Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. 1997; 65(10): 4146–4151.

  7. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J. et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002; 346(7): 491–496.

  8. Benjamin D.K., Schelonka R., White R., Holley H.P., Bifano E., Cummings J. et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006; 26(5): 290–295.

  9. Rupp M.E., Holley H.P. Jr., Lutz J., Dicpinigaitis P.V., Woods C.W., Levine D.P. et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2007; 51(12): 4249–4254.

  10. Ruppitsch W., Stoger A., Schmid D., Fretz R., Indra A., Allerberger F. et al. Occurrence of the USA300 community-acquired Staphylococcus aureus clone in Austria. Euro Surveill. 2007; 12(10): E071025.1.

  11. Witte W., Strommenger B., Cuny C., Heuck D., Nuebel U. Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J. Antimicrob. Chemother. 2007; 60(6): 1258–1263.

  12. Schaffer A.C., Lee J.C. Staphylococcal vaccines and immunotherapies. Infect. Dis. Clin. North. Am. 2009; 23(1): 153–171.

  13. Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin. Biol. Ther. 2010; 10(7): 1049–1059. doi:10.1517/14712598.2010.495115.

  14. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 2008; 205(2): 287–294.

  15. Lee S.S., Kim Y.J., Chung D.R., Jung K.S., Kim J.S. Invasive Infection Caused by Community-Associated Methicillin- Resistant Staphylococcus aureus Strain Not Carrying Panton-Valentine Leukocidin in Korea. J. Clin. Microbiol. 2009; 48(1): 311–313.

  16. Rollason J., Bastin L., Hilton A.C., Pillay D.G., Worthington T., McKeon C. et al. Epidemiology of community-acquired meticillin-resistant Staphylococcus aureus obtained from the UK West Midlands region. J. Hosp. Infect. 2008; 70(4): 314–320.

  17. Voyich J.M., Otto M., Mathema B., Braughton K.R., Whitney A.R., Welty D. et al. Is Panton-Valentine Leukocidin the Major Virulence Determinant in Community-Associated Methicillin-Resistant Staphylococcus aureus Disease? J. Infect. Dis. 2006; 194(12): 1761–1770.

  18. Brown E.L., Dumitrescu O., Thomas D., Badiou C., Koers E.M., Choudhury P. et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 2008; 15(2): 156–164.

  19. Bubeck Wardenburg J., Palazzolo-Ballance A.M., Otto M., Schneewind O., DeLeo F.R. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillinresistant Staphylococcus aureus disease. J. Infect. Dis. 2008; 198(8): 1166–1170.

  20. Diep B.A., Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 2008; 16(8): 361–369.

  21. Josefsson E., Hartford O., O’Brien L., Patti J.M., Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J. Infect. Dis. 2001; 184(12): 1572–1580.

  22. Medzhitov R., Janway Jr. C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298–300.

  23. Medzhitov R., Janway Jr.C.A. Innate immune induction of the adaptive immune response. Cold Spring. Harb. Symp. Quant. Biol 2002; 64: 429–435.

  24. Rosengren A.T., Nyman T.A., Lashesman R. Proteonic profiling of interleukine 12 treated human T-helper cells. Proteomics 2005; 5(12): 3137–3141.

  25. Etz H., Minh D.B., Henics T., Dryla A., Winkler B., Triska C. et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2002; 99(10): 6573–6578.

  26. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T. et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun. 2006; 74(4): 2215–2223.

  27. Torres V.J., Pishchany G., Humayun M., Schneewind O., Skaar E.P. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J. Bacteriol. 2006; 188(24): 8421–8429.

  28. Intercell in trouble as Merck stops MRSA vaccine trial. World News, 09.06.2011.

  29. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2006; 103(45): 16942–16947.

  30. Posey J.E., Gherardini F.C. Lack of a role for iron in the Lyme disease pathogen. Science 2000; 288(5471): 1651–1653.

  31. Skaar E.P., Schneewind O. Iron-regulated surface determinants (Isd) of Staphylococcus aureus: stealing iron from heme. Microbes Infect. 2004; 6(4): 390–397.

  32. Stauff D.L., Skaar E.P. The heme sensor system of Staphylococcus aureus. Contrib. Microbiol. 2009; 16: 120–135.

  33. Lin L., Ibrahim A.S., Xin X., Farber J. M., Avanesian V., Baquir B. et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009; 5(12): e1000703. doi:10.1371/journal.ppat.1000703.

  34. Spellberg B, Daum R. A new view on development of Staphylococcus aureus vaccine. Hum. Vaccin. 2010; 6(10): 857–859.

  35. Spellberg B., Ibrahim A.S., Yeaman M.R., Lin L., Fu Y., Avanesian V. et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect. Immun. 2008; 76(10): 4574–4580.

  36. McDevitt D., Francois P., Vaudaux P., Foster T.J. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol. Microbiol. 1994; 11(2): 237–248.

  37. Foster TJ, Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 1998; 6(12): 484–488.

  38. Vernachio J.H., Bayer A.S., Ames B., Bryant D., Prater B.D., Syribeys P.J. et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob. Agents Chemother. 2006; 50(2): 511–518.

  39. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M. et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007; 151(3): 260–265.

  40. Patti J.M.. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 2004; 22(Suppl 1): S39–S43.

  41. Weems J.J.Jr., Steinberg J.P., Filler S., Baddley J.W., Corey G.R., Sampathkumar P. et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006; 50(8): 2751–2755.

  42. Foster T.J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005; 3(12): 948–958.

  43. DeLeo F.R., Otto M. An antidote for Staphylococcus aureus pneumonia? J. Exp. Med. 2008; 205(2): 271–274.

  44. Szmigielski S., Prevost G., Monteil H., Colin D.A., Jeljaszewicz J. Leukocidal toxins of staphylococci. Zentralbl. Bakteriol. 1999; 289(2): 185–201.

  45. Wang R., Braughton K.R., Kretschmer D., Bach T.H., Queck S.Y., Li M. et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 2007; 13(12): 1510–1514.

  46. Efremova V.N., Egorova N.B., Masyukova S.A. Beskletochnaya antistafilokokkovaya vaktsina dlya lecheniya hronicheskoy stafilokokkovoy infektsii [Acellular antistaphylococcal vaccine for therapy the chronic staphylococcal infection]. Patent RU. № 2122862, 1998. (In Russ.)

  47. Egorova N.B., Efremova V.N., Kurbatova E.A., Gruber I.M. [Experimental, clinical and immunologic assessment of acellular staphylococcal vaccine «Staphylovac»]. Zhurnal Еpidemiologii, Mikrobiologii i Immunologii 2008; (6): 102–108. (In Russ.)

  48. Masyukova S.A., Gladko V.V., Ustinov M.V., Vladimirova E.V., Tarasenko G.N., Sorokina E.V. [Bacterial dermatological infections and their significance in clinical practice of dermatologists]. Consilium medicum 2004; 6(3): 180–185. (In Russ.)

  49. Sorokina E.V. Bakterialnyie vaktsinyi v terapii hronicheskoy piodermii [Bacterial vaccines in therapy of chronic pyodermia]. Autoabstract candidate of science. Moscow, 2006. (In Russ.)

  50. Kuzmenko O.M., Zlygostev S.A., Mikhailova N.A., Gruber I.M., Akhmatova N.K., Egorova N.B., Kurbatova E.A., Cherkasova L.S. [Characteristics of antigenic complexes of Staphylococcus aureus vaccine strains obtained in different cultivation conditions]. Zhurnal Еpidemiologii, Mikrobiologii i Immunologii 2010; (2): 51–54. (In Russ.)

About the Autors

Prof. Gruber Irina Mironovna, MD; Head, Laboratory of Experimental Microbiology, I.I. Mechnikov Research Institute of Vaccines and Sera, Russian Academy of Medical Sciences
Address: 5a, Malyi Kazennyi Per., Moscow 105064
Telephone: +7(495) 916–20–47

Бионика Медиа